SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:ac90b591-ad2e-47e6-8a67-578a2ede9cb0"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:ac90b591-ad2e-47e6-8a67-578a2ede9cb0" > Pregnenolone for th...

Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease

Corsi, Sara (författare)
University of Cagliari
Scheggi, Simona (författare)
University of Siena
Pardu, Alessandra (författare)
University of Cagliari
visa fler...
Braccagni, Giulia (författare)
University of Siena
Caruso, Donatella (författare)
University of Milan
Cioffi, Lucia (författare)
University of Milan
Diviccaro, Silvia (författare)
University of Milan
Gentile, Mauro (författare)
University of Cagliari
Fanni, Silvia (författare)
Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Dermatologi och venereologi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Basal Ganglia Pathophysiology,Lund University Research Groups,Dermatology and Venereology (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Cagliari
Stancampiano, Roberto (författare)
University of Cagliari
Gambarana, Carla (författare)
University of Siena
Melcangi, Roberto Cosimo (författare)
University of Milan
Frau, Roberto (författare)
University of Cagliari
Carta, Manolo (författare)
University of Cagliari
visa färre...
 (creator_code:org_t)
Elsevier BV, 2023
2023
Engelska.
Ingår i: Experimental Neurology. - : Elsevier BV. - 0014-4886. ; 363
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Growing preclinical and clinical evidence highlights neurosteroid pathway imbalances in Parkinson's Disease (PD) and L-DOPA-induced dyskinesias (LIDs). We recently reported that 5α-reductase (5AR) inhibitors dampen dyskinesias in parkinsonian rats; however, unraveling which specific neurosteroid mediates this effect is critical to optimize a targeted therapy. Among the 5AR-related neurosteroids, striatal pregnenolone has been shown to be increased in response to 5AR blockade and decreased after 6-OHDA lesions in the rat PD model. Moreover, this neurosteroid rescued psychotic-like phenotypes by exerting marked antidopaminergic activity. In light of this evidence, we investigated whether pregnenolone might dampen the appearance of LIDs in parkinsonian drug-naïve rats. We tested 3 escalating doses of pregnenolone (6, 18, 36 mg/kg) in 6-OHDA-lesioned male rats and compared the behavioral, neurochemical, and molecular outcomes with those induced by the 5AR inhibitor dutasteride, as positive control. The results showed that pregnenolone dose-dependently countered LIDs without affecting L-DOPA-induced motor improvements. Post-mortem analyses revealed that pregnenolone significantly prevented the increase of validated striatal markers of dyskinesias, such as phospho-Thr-34 DARPP-32 and phospho-ERK1/2, as well as D1-D3 receptor co-immunoprecipitation in a fashion similar to dutasteride. Moreover, the antidyskinetic effect of pregnenolone was paralleled by reduced striatal levels of BDNF, a well-established factor associated with the development of LIDs. In support of a direct pregnenolone effect, LC/MS-MS analyses revealed that striatal pregnenolone levels strikingly increased after the exogenous administration, with no significant alterations in downstream metabolites. All these data suggest pregnenolone as a key player in the antidyskinetic properties of 5AR inhibitors and highlight this neurosteroid as an interesting novel tool to target LIDs in PD.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

6-OHDA-lesion
Dyskinesia
Neurosteroids
Parkinson's disease
Pregnenolone

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy